ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:00 AM | Thursday | Jun 25, 2026 PRNewsWire

Abbott hosts conference call for second-quarter earnings

News Thumbnail
8:30 AM | Wednesday | Jun 24, 2026 PRNewsWire

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

News Thumbnail
12:00 PM | Monday | Jun 22, 2026 PRNewsWire

New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

News Thumbnail
9:00 AM | Monday | Jun 8, 2026 PRNewsWire

New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

News Thumbnail
9:00 AM | Saturday | Jun 6, 2026 PRNewsWire

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

News Thumbnail
9:00 AM | Wednesday | May 27, 2026 PRNewsWire

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

News Thumbnail
7:01 AM | Wednesday | May 27, 2026 PRNewsWire

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

News Thumbnail
9:00 AM | Tuesday | May 26, 2026 PRNewsWire

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

News Thumbnail
9:00 AM | Tuesday | Apr 28, 2026 PRNewsWire

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

News Thumbnail
12:30 PM | Saturday | Apr 25, 2026 PRNewsWire

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

News Thumbnail

Abbott hosts conference call for second-quarter earnings

PRNewsWire

9:00 AM | Thursday | Jun 25, 2026

news photo
Loading...

ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.

Read full article redirect
9:00 AM | Thursday | Jun 25, 2026

Abbott hosts conference call for second-quarter earnings

PRNewsWire

ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Jun 24, 2026

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

PRNewsWire

ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc.,  the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease.

Read full article arrow
News Thumbnail
12:00 PM | Monday | Jun 22, 2026

New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

PRNewsWire

Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents Through the new "Love Without Measure" initiative, Similac is standing with parents in promoting more authentic portrayals of parenthood and pushing back on comparison culture ABBOTT PARK, Ill., June 22, 2026 /PRNewswire/ -- Parenthood is widely anticipated as one of life's most fulfilling journeys, yet for today's new parents – especially Gen Z – that excitement is often met with feelings of pressure and judgment and amplified by picture-perfect social media portrayals.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Jun 8, 2026

New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

PRNewsWire

Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements Abbott's Healthy Food Rx program is a Food is Medicine initiative delivering recipe-based food boxes and nutrition education to people living with diabetes NEW ORLEANS, June 8, 2026 /PRNewswire/ -- New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating in Abbott's (NYSE: ABT) Healthy Food Rx "Food is Medicine" program, paired with community health worker–led coaching, experienced major improvements in healthy eating, physical activity, diabetes self-management, food insecurity and self-reported physical and mental health. Conducted with the Public Health Institute Center for Wellness and Nutrition (PHI CWN), the Asian Pacific Self-Development and Residential Association (APSARA) and the Emergency... Read more

Read full article arrow
News Thumbnail
9:00 AM | Saturday | Jun 6, 2026

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

PRNewsWire

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 27, 2026

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

PRNewsWire

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.

Read full article arrow
News Thumbnail
7:01 AM | Wednesday | May 27, 2026

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

PRNewsWire

Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | May 26, 2026

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

PRNewsWire

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Apr 28, 2026

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

PRNewsWire

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.
S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software.

Read full article arrow
News Thumbnail
12:30 PM | Saturday | Apr 25, 2026

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

PRNewsWire

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical... Read more

Read full article arrow
News Thumbnail